ArticleInternational journal of molecular sciences2025
Dose-Dependent Effects of Myo-Inositol on Kainic Acid-Induced Epilepsy: Electrophysiological, Behavioral, Transcriptomic, and DNA Methylome Studies.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A patient with a rare metabolic disease and myo-inositol administration leading to a new treatment for epilepsy.Molecular genetics and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epilepsy is a prevalent neurological disorder characterized by spontaneous recurrent seizures (SRS). Epileptogenesis is a multifaceted pathophysiological process that transforms a normal brain into one prone to chronic seizures. Targeting epileptogenesis is a compelling line of epilepsy therapy. Thus, discovering new drugs that oppose, mitigate, or modify epileptogenesis is a significant challenge in modern neuroscience. Our previous work demonstrated that, in a kainic acid (KA)-induced post-status epilepticus model, 28 days myo-inositol (MI) treatment reduces frequency and duration of motor and electrographic SRS even following cessation of treatment, for the following 4 weeks and identified MI as a promising antiepileptogenic compound To further evaluate the dose-dependent efficacy of MI, we applied the same experimental model using 30 mg/kg (dose used in earlier studies), 60 mg/kg, and 120 mg/kg to assess effects on hippocampal electrographic and motor SRS, as well as KA-induced spatial learning and memory impairment in a Morris water maze test. We found that MI had long-lasting, dose-dependent suppressive effects on behavioral and electrographic manifestations of epileptogenesis and ameliorated spatial learning and memory deficit induced by SE, with 60 mg/kg emerging as the most effective dose. Furthermore, we investigated transcriptomic and epigenetic alterations associated with the optimal MI dose and identified multiple affected pathways in the hippocampus. Interestingly, MI treatment resulted in transcriptomic upregulation and prevention of downregulation of several ion channel subunits, including GRIK3 and GRIN3A (kainate and NMDA receptor subunits) and the sodium channel subunit SCNB4. The obtained data highlight new molecular targets for epilepsy therapy and support the translational potential of MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.